Document Detail

Clinical experience using Cortoss for treating vertebral compression fractures with vertebroplasty and kyphoplasty: twenty four-month follow-up.
MedLine Citation:
PMID:  20844420     Owner:  NLM     Status:  MEDLINE    
STUDY DESIGN: Forty patients were enrolled in 2 FDA-approved pilot Investigational Device Exemption (IDE) studies using Cortoss for the treatment of vertebral compression fractures (VCF). Twenty patients were treated at 3 centers, using vertebroplasty (VP) and 20 patients were treated at 5 centers, using kyphoplasty (KP).
OBJECTIVE: To assess the feasibility and clinical outcomes using Cortoss to treat osteoporotic VCF.
SUMMARY OF BACKGROUND DATA: Cortoss is an injectable bioactive, self-setting, radiopaque composite shown to stabilize and provide immediate weight bearing support to fractured vertebrae. Cortoss is approved for use in Europe for both screw and vertebral augmentation. METHODS.: Patient assessments were conducted before surgery and after surgery through 24 months using Visual Analog Scale (VAS), Oswestry Disability Index (ODI), and quality-of-life assessment (SF-12) questionnaires. Extravasations were evaluated using radiographs and CT scans.
RESULTS: Immediate pain improvement was seen in VP patients with VAS scores decreasing from 75.7 before surgery to 35.9 at 72 hours. Continued improvement from baseline was seen out to 2 years (average VAS of 48.9). Disability improved with average ODI scores decreasing from 52.2% preoperative to 38.3% at 2 years for VP patients. Immediate pain improvement was also seen in KP patients with VAS scores decreasing from 78.1 before surgery to 42.7 at 72 hours. Continued improvement from baseline was seen out to 2 years (average VAS of 25.4). ODI scores improved from 60.5% preoperative to 34.5% at 2 years for KP patients. Average material volumes injected were 1.85 mL for VP and 4.13 mL for KP. Extravasations from both techniques were minor, anatomically close to the treated vertebrae and asymptomatic. No cardiac irregularities or pulmonary emboli were observed.
CONCLUSION: These studies indicate Cortoss is safe and effective in treating osteoporotic VCF using vertebroplasty or kyphoplasty. Pain relief and restoration of function with Cortoss is comparable to results found in the literature for polymethylmethacrylate.
Hyun Bae; Michael Shen; Philip Maurer; Walter Peppelman; William Beutler; Raymond Linovitz; Erik Westerlund; Timothy Peppers; Isador Lieberman; Choll Kim; Federico Girardi
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  Spine     Volume:  35     ISSN:  1528-1159     ISO Abbreviation:  Spine     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-16     Completed Date:  2011-01-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7610646     Medline TA:  Spine (Phila Pa 1976)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  E1030-6     Citation Subset:  IM    
The Spine Institute, Santa Monica, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Bisphenol A-Glycidyl Methacrylate / adverse effects,  therapeutic use*
Disability Evaluation
Feasibility Studies
Follow-Up Studies
Fractures, Compression / surgery*
Kyphoplasty / methods*
Longitudinal Studies
Middle Aged
Pain Measurement
Quality of Life
Spinal Fractures / surgery*
Treatment Outcome
Vertebroplasty / methods*
Reg. No./Substance:
0/CORTOSS; 1565-94-2/Bisphenol A-Glycidyl Methacrylate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Re: Kleeman TJ, Ahn UM, Talbot-Kleeman A. Laparoscopic anterior lumbar interbody fusion with rhBMP-2...
Next Document:  The impact of intermittent retraction on paraspinal muscle function during lumbar surgery.